Brazilian External Quality Assessment Program for serum total cholesterol – A report from 2007 to 2023
Year: 2024
Type: conference-abstract
Abstract: Objective: Serum total cholesterol (STC) measurement plays a critical role in cardiovascular risk (CR) assessment. While clinical laboratories (CL) in high-income countries report deviations with the coefficients of variation (CV) ranging from 1.0 to 3.7%, performance in CL from low- and middle-income countries remains a gap. This study assessed the diagnostic proficiency of CL participating in a Brazilian external quality assessment program (EQAP) for STC. Method: The EQAP conducted four surveys/year, with participants analyzing three lyophilized human serum samples per survey. Data analyzed included the number of participants, analytical methods used, and average and median CVs for each method. Conclusion: A total of 4,107 participants contributed to 292,240 datasets. The overall average CV was 6.4%, decreasing from 7.8% in 2007 to 5.4% in 2023. In 2007, the main analytical systems included Roche Cobas Mira/Mira Plus (34%), BioPlus Bio2000 (15%), Express Plus/550 (10%), Selectra 2 (7%), and other systems (34%). By 2023, the main systems were AU 480 (13%), Cobas c501 (13%), Integra 400/400 Plus (13%), Cobas Mira/S/Plus/Plus CC (13%), and other systems (48%). Variations in CV were observed across the assessed methodologies, with the CHOLIP method exhibiting a higher CV. The consistent decline in CV over the study period, reaching 5.4% in 2023, underscores thecritical role of EQAPs in improving CL standards. Additionally, the adoption of new analytical systems during this timeframe highlights the influence of advancing technologies on CL performance. Given the significance of STC in CR stratification, this research highlighted the essential role of EQAPs in monitoring CL quality.
Language: English
Subfield: Medical Laboratory Technology
Field: Health Professions
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4409418418
